LINGEGOWDA SELANEREMANGALALINGEGOWDA SELANERE MANGALA9112MANGALA, LINGEGOWDA SELANEREInstructorprns:coAuthorOfcoauthor ofFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:personInPositionpositionsPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson7777 Knight RdHouston77054-3005TXAuthorship 1716072Authorship 1764171Authorship 17954113Authorship 17970311Authorship 1816416Authorship 1843468Authorship 1850485Authorship 1935023Authorship 195046812914941Kittur FS, Mangala SL, Rus'd AA, Kitaoka M, Tsujibo H, Hayashi KFEBS lettersFusion of family 2b carbohydrate-binding module increases the catalytic activity of a xylanase from Thermotoga maritima to soluble xylan. FEBS Lett. 2003 Aug 14; 549(1-3):147-51.FEBS Lett2003-08-14T00:00:002003Fusion of family 2b carbohydrate-binding module increases the catalytic activity of a xylanase from Thermotoga maritima to soluble xylan.16153302Mangala LS, Arun B, Sahin AA, Mehta KMolecular cancerTissue transglutaminase-induced alterations in extracellular matrix inhibit tumor invasion. Mol Cancer. 2005 Sep 09; 4:33.Mol Cancer2005-09-09T00:00:002005Tissue transglutaminase-induced alterations in extracellular matrix inhibit tumor invasion.19395869Shahzad MM, Lu C, Lee JW, Stone RL, Mitra R, Mangala LS, Lu Y, Baggerly KA, Danes CG, Nick AM, Halder J, Kim HS, Vivas-Mejia P, Landen CN, Lopez-Berestein G, Coleman RL, Sood AKCancer biology & therapyDual targeting of EphA2 and FAK in ovarian carcinoma. Cancer Biol Ther. 2009 Jun; 8(11):1027-34.Cancer Biol Ther2009-06-24T00:00:002009Dual targeting of EphA2 and FAK in ovarian carcinoma.20009575Lu C, Shahzad MM, Moreno-Smith M, Lin YG, Jennings NB, Allen JK, Landen CN, Mangala LS, Armaiz-Pena GN, Schmandt R, Nick AM, Stone RL, Jaffe RB, Coleman RL, Sood AKCancer biology & therapyTargeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models. Cancer Biol Ther. 2010 Feb; 9(3):176-82.Cancer Biol Ther2010-02-16T00:00:002010Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models.Experimental TherapeuticsGynecological Oncology & Reproductive MedicineLeukemiaSystems BiologyMD AndersonGABRIELLOPEZGABRIEL LOPEZ8612LOPEZ, GABRIELProfessorHAGOP MKANTARJIANHAGOP M KANTARJIAN8501KANTARJIAN, HAGOP MProfessorGORDON BMILLSGORDON B MILLS8620MILLS, GORDON BProfessorROBERTCOLEMANROBERT COLEMAN9184COLEMAN, ROBERTProfessorSUNILAPRADEEPSUNILA PRADEEP9724PRADEEP, SUNILAInstructor2.3870.00570993522research areas16.58630.020314473coauthor of215.11215.153160similar to11152selected publicationsGEORGE ACALINGEORGE A CALIN9408CALIN, GEORGE AProfessorANIL KSOODANIL K SOOD9048SOOD, ANIL KProfessorAuthorship 2229592Authorship 22312313Authorship 2266441Authorship 2280232Authorship 2285462Authorship 2291352Authorship 22939310Authorship 2294202Authorship 2304392Authorship 2307071Authorship 23297219Authorship 2344475Authorship 23463223Authorship 234699915907844Kim BJ, Mangala SL, Hayashi KFEBS lettersCo-refolding of two peptide fragments derived from Agrobacterium tumefaciens beta-glucosidase with catalytic activity. FEBS Lett. 2005 Jun 06; 579(14):3075-80.FEBS Lett2005-06-06T00:00:002005Co-refolding of two peptide fragments derived from Agrobacterium tumefaciens beta-glucosidase with catalytic activity.16862152Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, Jennings NB, Armaiz-Pena G, Bankson JA, Ravoori M, Merritt WM, Lin YG, Mangala LS, Kim TJ, Coleman RL, Landen CN, Li Y, Felix E, Sanguino AM, Newman RA, Lloyd M, Gershenson DM, Kundra V, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AKNature medicineChronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med. 2006 Aug; 12(8):939-44.Nat Med2006-07-23T00:00:002006Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma.18632639Hwang JY, Mangala LS, Fok JY, Lin YG, Merritt WM, Spannuth WA, Nick AM, Fiterman DJ, Vivas-Mejia PE, Deavers MT, Coleman RL, Lopez-Berestein G, Mehta K, Sood AKCancer researchClinical and biological significance of tissue transglutaminase in ovarian carcinoma. Cancer Res. 2008 Jul 15; 68(14):5849-58.Cancer Res2008-07-15T00:00:002008Clinical and biological significance of tissue transglutaminase in ovarian carcinoma.19470734Mangala LS, Zuzel V, Schmandt R, Leshane ES, Halder JB, Armaiz-Pena GN, Spannuth WA, Tanaka T, Shahzad MM, Lin YG, Nick AM, Danes CG, Lee JW, Jennings NB, Vivas-Mejia PE, Wolf JK, Coleman RL, Siddik ZH, Lopez-Berestein G, Lutsenko S, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchTherapeutic Targeting of ATP7B in Ovarian Carcinoma. Clin Cancer Res. 2009 Jun 01; 15(11):3770-80.Clin Cancer Res2009-05-26T00:00:002009Therapeutic Targeting of ATP7B in Ovarian Carcinoma.20388851Lee JW, Stone RL, Lee SJ, Nam EJ, Roh JW, Nick AM, Han HD, Shahzad MM, Kim HS, Mangala LS, Jennings NB, Mao S, Gooya J, Jackson D, Coleman RL, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchEphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma. Clin Cancer Res. 2010 May 01; 16(9):2562-70.Clin Cancer Res2010-04-13T00:00:002010EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma.20430760Tanaka T, Mangala LS, Vivas-Mejia PE, Nieves-Alicea R, Mann AP, Mora E, Han HD, Shahzad MM, Liu X, Bhavane R, Gu J, Fakhoury JR, Chiappini C, Lu C, Matsuo K, Godin B, Stone RL, Nick AM, Lopez-Berestein G, Sood AK, Ferrari MCancer researchSustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res. 2010 May 01; 70(9):3687-96.Cancer Res2010-05-01T00:00:002010Sustained small interfering RNA delivery by mesoporous silicon particles.20682653Spannuth WA, Mangala LS, Stone RL, Carroll AR, Nishimura M, Shahzad MM, Lee SJ, Moreno-Smith M, Nick AM, Liu R, Jennings NB, Lin YG, Merritt WM, Coleman RL, Vivas-Mejia PE, Zhou Y, Krasnoperov V, Lopez-Berestein G, Gill PS, Sood AKMolecular cancer therapeuticsConverging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma. Mol Cancer Ther. 2010 Aug; 9(8):2377-88.Mol Cancer Ther2010-08-03T00:00:002010Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma.21472135Shahzad MM, Mangala LS, Han HD, Lu C, Bottsford-Miller J, Nishimura M, Mora EM, Lee JW, Stone RL, Pecot CV, Thanapprapasr D, Roh JW, Gaur P, Nair MP, Park YY, Sabnis N, Deavers MT, Lee JS, Ellis LM, Lopez-Berestein G, McConathy WJ, Prokai L, Lacko AG, Sood AKNeoplasia (New York, N.Y.)Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. Neoplasia. 2011 Apr; 13(4):309-19.Neoplasia2011-04-01T00:00:002011Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles.21775437Mangala LS, Zhang Y, He Z, Emami K, Ramesh GT, Story M, Rohde LH, Wu HThe Journal of biological chemistryEffects of simulated microgravity on expression profile of microRNA in human lymphoblastoid cells. J Biol Chem. 2011 Sep 16; 286(37):32483-90.J Biol Chem2011-07-20T00:00:002011Effects of simulated microgravity on expression profile of microRNA in human lymphoblastoid cells.22510595He Z, Mangala LS, Theriot CA, Rohde LH, Wu H, Zhang YJournal of radiation researchCell killing and radiosensitizing effects of atorvastatin in PC3 prostate cancer cells. J Radiat Res. 2012; 53(2):225-33.J Radiat Res2012-01-01T00:00:002012Cell killing and radiosensitizing effects of atorvastatin in PC3 prostate cancer cells.23585472Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, Langley RR, Jennings NB, Ivan C, Coffin JE, Armaiz GN, Bottsford-Miller J, Kim SB, Halleck MS, Hendrix MJ, Bornman W, Bar-Eli M, Lee JS, Siddik ZH, Lopez-Berestein G, Sood AKThe Journal of clinical investigationATP11B mediates platinum resistance in ovarian cancer. J Clin Invest. 2013 May; 123(5):2119-30.J Clin Invest2013-04-15T00:00:002013ATP11B mediates platinum resistance in ovarian cancer.24018975Pecot CV, Rupaimoole R, Yang D, Akbani R, Ivan C, Lu C, Wu S, Han HD, Shah MY, Rodriguez-Aguayo C, Bottsford-Miller J, Liu Y, Kim SB, Unruh A, Gonzalez-Villasana V, Huang L, Zand B, Moreno-Smith M, Mangala LS, Taylor M, Dalton HJ, Sehgal V, Wen Y, Kang Y, Baggerly KA, Lee JS, Ram PT, Ravoori MK, Kundra V, Zhang X, Ali-Fehmi R, Gonzalez-Angulo AM, Massion PP, Calin GA, Lopez-Berestein G, Zhang W, Sood AKNature communicationsTumour angiogenesis regulation by the miR-200 family. Nat Commun. 2013; 4:2427.Nat Commun2013-01-01T00:00:002013Tumour angiogenesis regulation by the miR-200 family.25026212Pradeep S, Kim SW, Wu SY, Nishimura M, Chaluvally-Raghavan P, Miyake T, Pecot CV, Kim SJ, Choi HJ, Bischoff FZ, Mayer JA, Huang L, Nick AM, Hall CS, Rodriguez-Aguayo C, Zand B, Dalton HJ, Arumugam T, Lee HJ, Han HD, Cho MS, Rupaimoole R, Mangala LS, Sehgal V, Oh SC, Liu J, Lee JS, Coleman RL, Ram P, Lopez-Berestein G, Fidler IJ, Sood AKCancer cellHematogenous metastasis of ovarian cancer: rethinking mode of spread. Cancer Cell. 2014 Jul 14; 26(1):77-91.Cancer Cell2014-07-14T00:00:002014Hematogenous metastasis of ovarian cancer: rethinking mode of spread.25043055Krzeszinski JY, Wei W, Huynh H, Jin Z, Wang X, Chang TC, Xie XJ, He L, Mangala LS, Lopez-Berestein G, Sood AK, Mendell JT, Wan YNaturemiR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2. Nature. 2014 Aug 28; 512(7515):431-5.Nature2014-06-25T00:00:002014miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2.Authorship 2475773Authorship 2479747Authorship 2518642Authorship 2520541Authorship 2521524Authorship 2544144Authorship 2546163Authorship 25632712Authorship 260315616146723Mehta K, Fok JY, Mangala LSFrontiers in bioscience : a journal and virtual libraryTissue transglutaminase: from biological glue to cell survival cues. Front Biosci. 2006 Jan 01; 11:173-85.Front Biosci2006-01-01T00:00:002006Tissue transglutaminase: from biological glue to cell survival cues.17077358Landen CN, Lu C, Han LY, Coffman KT, Bruckheimer E, Halder J, Mangala LS, Merritt WM, Lin YG, Gao C, Schmandt R, Kamat AA, Li Y, Thaker P, Gershenson DM, Parikh NU, Gallick GE, Kinch MS, Sood AKJournal of the National Cancer InstituteEfficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. J Natl Cancer Inst. 2006 Nov 01; 98(21):1558-70.J Natl Cancer Inst2006-11-01T00:00:002006Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.18765535Lin YG, Immaneni A, Merritt WM, Mangala LS, Kim SW, Shahzad MM, Tsang YT, Armaiz-Pena GN, Lu C, Kamat AA, Han LY, Spannuth WA, Nick AM, Landen CN, Wong KK, Gray MJ, Coleman RL, Bodurka DC, Brinkley WR, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchTargeting aurora kinase with MK-0457 inhibits ovarian cancer growth. Clin Cancer Res. 2008 Sep 01; 14(17):5437-46.Clin Cancer Res2008-09-01T00:00:002008Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth.19383821Armaiz-Pena GN, Mangala LS, Spannuth WA, Lin YG, Jennings NB, Nick AM, Langley RR, Schmandt R, Lutgendorf SK, Cole SW, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchEstrous cycle modulates ovarian carcinoma growth. Clin Cancer Res. 2009 May 01; 15(9):2971-8.Clin Cancer Res2009-04-21T00:00:002009Estrous cycle modulates ovarian carcinoma growth.19495686Mangala LS, Han HD, Lopez-Berestein G, Sood AKMethods in molecular biology (Clifton, N.J.)Liposomal siRNA for ovarian cancer. Methods Mol Biol. 2009; 555:29-42.Methods Mol Biol2009-01-01T00:00:002009Liposomal siRNA for ovarian cancer.19829059Kim TJ, Landen CN, Lin YG, Mangala LS, Lu C, Nick AM, Stone RL, Merritt WM, Armaiz-Pena G, Jennings NB, Coleman RL, Tice DA, Sood AKCancer biology & therapyCombined anti-angiogenic therapy against VEGF and integrin alphaVbeta3 in an orthotopic model of ovarian cancer. Cancer Biol Ther. 2009 Dec; 8(23):2263-72.Cancer Biol Ther2009-12-19T00:00:002009Combined anti-angiogenic therapy against VEGF and integrin alphaVbeta3 in an orthotopic model of ovarian cancer.20708159Lu C, Han HD, Mangala LS, Ali-Fehmi R, Newton CS, Ozbun L, Armaiz-Pena GN, Hu W, Stone RL, Munkarah A, Ravoori MK, Shahzad MM, Lee JW, Mora E, Langley RR, Carroll AR, Matsuo K, Spannuth WA, Schmandt R, Jennings NB, Goodman BW, Jaffe RB, Nick AM, Kim HS, Guven EO, Chen YH, Li LY, Hsu MC, Coleman RL, Calin GA, Denkbas EB, Lim JY, Lee JS, Kundra V, Birrer MJ, Hung MC, Lopez-Berestein G, Sood AKCancer cellRegulation of tumor angiogenesis by EZH2. Cancer Cell. 2010 Aug 09; 18(2):185-97.Cancer Cell2010-08-09T00:00:002010Regulation of tumor angiogenesis by EZH2.21300758Kim HS, Han HD, Armaiz-Pena GN, Stone RL, Nam EJ, Lee JW, Shahzad MM, Nick AM, Lee SJ, Roh JW, Nishimura M, Mangala LS, Bottsford-Miller J, Gallick GE, Lopez-Berestein G, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchFunctional roles of Src and Fgr in ovarian carcinoma. Clin Cancer Res. 2011 Apr 01; 17(7):1713-21.Clin Cancer Res2011-02-07T00:00:002011Functional roles of Src and Fgr in ovarian carcinoma.23871637Masiero M, Sim?es FC, Han HD, Snell C, Peterkin T, Bridges E, Mangala LS, Wu SY, Pradeep S, Li D, Han C, Dalton H, Lopez-Berestein G, Tuynman JB, Mortensen N, Li JL, Patient R, Sood AK, Banham AH, Harris AL, Buffa FMCancer cellA core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis. Cancer Cell. 2013 Aug 12; 24(2):229-41.Cancer Cell2013-07-18T00:00:002013A core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis.Authorship 2672573Authorship 2682195Authorship 2687735Authorship 271627617106249Landen CN, Merritt WM, Mangala LS, Sanguino AM, Bucana C, Lu C, Lin YG, Han LY, Kamat AA, Schmandt R, Coleman RL, Gershenson DM, Lopez-Berestein G, Sood AKCancer biology & therapyIntraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer. Cancer Biol Ther. 2006 Dec; 5(12):1708-13.Cancer Biol Ther2006-12-30T00:00:002006Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer.19058181Spannuth WA, Nick AM, Jennings NB, Armaiz-Pena GN, Mangala LS, Danes CG, Lin YG, Merritt WM, Thaker PH, Kamat AA, Han LY, Tonra JR, Coleman RL, Ellis LM, Sood AKInternational journal of cancerFunctional significance of VEGFR-2 on ovarian cancer cells. Int J Cancer. 2009 Mar 01; 124(5):1045-53.Int J Cancer2009-03-01T00:00:002009Functional significance of VEGFR-2 on ovarian cancer cells.19351748Lee JW, Shahzad MM, Lin YG, Armaiz-Pena G, Mangala LS, Han HD, Kim HS, Nam EJ, Jennings NB, Halder J, Nick AM, Stone RL, Lu C, Lutgendorf SK, Cole SW, Lokshin AE, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchSurgical stress promotes tumor growth in ovarian carcinoma. Clin Cancer Res. 2009 Apr 15; 15(8):2695-702.Clin Cancer Res2009-04-07T00:00:002009Surgical stress promotes tumor growth in ovarian carcinoma.24743243Hu W, Liu T, Ivan C, Sun Y, Huang J, Mangala LS, Miyake T, Dalton HJ, Pradeep S, Rupaimoole R, Previs RA, Han HD, Bottsford-Miller J, Zand B, Kang Y, Pecot CV, Nick AM, Wu SY, Lee JS, Sehgal V, Ram P, Liu J, Tucker SL, Lopez-Berestein G, Baggerly KA, Coleman RL, Sood AKCancer researchNotch3 pathway alterations in ovarian cancer. Cancer Res. 2014 Jun 15; 74(12):3282-93.Cancer Res2014-04-17T00:00:002014Notch3 pathway alterations in ovarian cancer.Authorship 2729831Authorship 2734049Authorship 2739755Authorship 2742112Authorship 274228715746533Mangala LS, Mehta KProgress in experimental tumor researchTissue transglutaminase (TG2) in cancer biology. Prog Exp Tumor Res. 2005; 38:125-38.Prog Exp Tumor Res2005-01-01T00:00:002005Tissue transglutaminase (TG2) in cancer biology.19641174Lee JW, Han HD, Shahzad MM, Kim SW, Mangala LS, Nick AM, Lu C, Langley RR, Schmandt R, Kim HS, Mao S, Gooya J, Fazenbaker C, Jackson D, Tice DA, Landen CN, Coleman RL, Sood AKJournal of the National Cancer InstituteEphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2009 Sep 02; 101(17):1193-205.J Natl Cancer Inst2009-07-29T00:00:002009EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma.19738426Merritt WM, Danes CG, Shahzad MM, Lin YG, Kamat AA, Han LY, Spannuth WA, Nick AM, Mangala LS, Stone RL, Kim HS, Gershenson DM, Jaffe RB, Coleman RL, Chandra J, Sood AKCancer biology & therapyAnti-angiogenic properties of metronomic topotecan in ovarian carcinoma. Cancer Biol Ther. 2009 Aug; 8(16):1596-603.Cancer Biol Ther2009-08-13T00:00:002009Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma.20538762Han HD, Mangala LS, Lee JW, Shahzad MM, Kim HS, Shen D, Nam EJ, Mora EM, Stone RL, Lu C, Lee SJ, Roh JW, Nick AM, Lopez-Berestein G, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchTargeted gene silencing using RGD-labeled chitosan nanoparticles. Clin Cancer Res. 2010 Aug 01; 16(15):3910-22.Clin Cancer Res2010-06-10T00:00:002010Targeted gene silencing using RGD-labeled chitosan nanoparticles.21531818Moreno-Smith M, Lu C, Shahzad MM, Pena GN, Allen JK, Stone RL, Mangala LS, Han HD, Kim HS, Farley D, Berestein GL, Cole SW, Lutgendorf SK, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchDopamine blocks stress-mediated ovarian carcinoma growth. Clin Cancer Res. 2011 Jun 01; 17(11):3649-59.Clin Cancer Res2011-04-29T00:00:002011Dopamine blocks stress-mediated ovarian carcinoma growth.Authorship 2920656Authorship 2921428Authorship 29236016Authorship 2981497Authorship 2984371Authorship 29945721Authorship 2996675Authorship 3018773Authorship 304893624755199Gharpure KM, Chu KS, Bowerman CJ, Miyake T, Pradeep S, Mangala SL, Han HD, Rupaimoole R, Armaiz-Pena GN, Rahhal TB, Wu SY, Luft JC, Napier ME, Lopez-Berestein G, DeSimone JM, Sood AKMolecular cancer therapeuticsMetronomic docetaxel in PRINT nanoparticles and EZH2 silencing have synergistic antitumor effect in ovarian cancer. Mol Cancer Ther. 2014 Jul; 13(7):1750-7.Mol Cancer Ther2014-04-22T00:00:002014Metronomic docetaxel in PRINT nanoparticles and EZH2 silencing have synergistic antitumor effect in ovarian cancer.25277212Leung CS, Yeung TL, Yip KP, Pradeep S, Balasubramanian L, Liu J, Wong KK, Mangala LS, Armaiz-Pena GN, Lopez-Berestein G, Sood AK, Birrer MJ, Mok SCNature communicationsCalcium-dependent FAK/CREB/TNNC1 signalling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potential. Nat Commun. 2014 Oct 03; 5:5092.Nat Commun2014-10-03T00:00:002014Calcium-dependent FAK/CREB/TNNC1 signalling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potential.25351346Rupaimoole R, Wu SY, Pradeep S, Ivan C, Pecot CV, Gharpure KM, Nagaraja AS, Armaiz-Pena GN, McGuire M, Zand B, Dalton HJ, Filant J, Miller JB, Lu C, Sadaoui NC, Mangala LS, Taylor M, van den Beucken T, Koch E, Rodriguez-Aguayo C, Huang L, Bar-Eli M, Wouters BG, Radovich M, Ivan M, Calin GA, Zhang W, Lopez-Berestein G, Sood AKNature communicationsHypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression. Nat Commun. 2014 Oct 29; 5:5202.Nat Commun2014-10-29T00:00:002014Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression.25416196Wen Y, Graybill WS, Previs RA, Hu W, Ivan C, Mangala LS, Zand B, Nick AM, Jennings NB, Dalton HJ, Sehgal V, Ram P, Lee JS, Vivas-Mejia PE, Coleman RL, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchImmunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer. Clin Cancer Res. 2015 Jan 15; 21(2):448-59.Clin Cancer Res2014-11-21T00:00:002014Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer.25995442Liu G, Yang D, Rupaimoole R, Pecot CV, Sun Y, Mangala LS, Li X, Ji P, Cogdell D, Hu L, Wang Y, Rodriguez-Aguayo C, Lopez-Berestein G, Shmulevich I, De Cecco L, Chen K, Mezzanzanica D, Xue F, Sood AK, Zhang WJournal of the National Cancer InstituteAugmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers. J Natl Cancer Inst. 2015 Jul; 107(7).J Natl Cancer Inst2015-05-20T00:00:002015Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers.26227489Reyes-Gonz?lez JM, Armaiz-Pe?a GN, Mangala LS, Valiyeva F, Ivan C, Pradeep S, Echevarr?a-Vargas IM, Rivera-Reyes A, Sood AK, Vivas-Mej?a PEMolecular cancer therapeuticsTargeting c-MYC in Platinum-Resistant Ovarian Cancer. Mol Cancer Ther. 2015 Oct; 14(10):2260-9.Mol Cancer Ther2015-07-30T00:00:002015Targeting c-MYC in Platinum-Resistant Ovarian Cancer.26313360Gaur S, Wen Y, Song JH, Parikh NU, Mangala LS, Blessing AM, Ivan C, Wu SY, Varkaris A, Shi Y, Lopez-Berestein G, Frigo DE, Sood AK, Gallick GEOncotargetChitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy. Oncotarget. 2015 Oct 06; 6(30):29161-77.Oncotarget2015-10-06T00:00:002015Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy.26389641Park YY, Sohn BH, Johnson RL, Kang MH, Kim SB, Shim JJ, Mangala LS, Kim JH, Yoo JE, Rodriguez-Aguayo C, Pradeep S, Hwang JE, Jang HJ, Lee HS, Rupaimoole R, Lopez-Berestein G, Jeong W, Park IS, Park YN, Sood AK, Mills GB, Lee JSHepatology (Baltimore, Md.)Yes-associated protein 1 and transcriptional coactivator with PDZ-binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma. Hepatology. 2016 Jan; 63(1):159-72.Hepatology2015-11-26T00:00:002015Yes-associated protein 1 and transcriptional coactivator with PDZ-binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma.26481148Pradeep S, Huang J, Mora EM, Nick AM, Cho MS, Wu SY, Noh K, Pecot CV, Rupaimoole R, Stein MA, Brock S, Wen Y, Xiong C, Gharpure K, Hansen JM, Nagaraja AS, Previs RA, Vivas-Mejia P, Han HD, Hu W, Mangala LS, Zand B, Stagg LJ, Ladbury JE, Ozpolat B, Alpay SN, Nishimura M, Stone RL, Matsuo K, Armaiz-Pe?a GN, Dalton HJ, Danes C, Goodman B, Rodriguez-Aguayo C, Kruger C, Schneider A, Haghpeykar S, Jaladurgam P, Hung MC, Coleman RL, Liu J, Li C, Urbauer D, Lopez-Berestein G, Jackson DB, Sood AKCancer cellErythropoietin Stimulates Tumor Growth via EphB4. Cancer Cell. 2015 Nov 09; 28(5):610-622.Cancer Cell2015-10-17T00:00:002015Erythropoietin Stimulates Tumor Growth via EphB4.26721492Hatakeyama H, Wu SY, Mangala LS, Lopez-Berestein G, Sood AKMethods in molecular biology (Clifton, N.J.)Assessment of In Vivo siRNA Delivery in Cancer Mouse Models. Methods Mol Biol. 2016; 1402:189-197.Methods Mol Biol2016-01-01T00:00:002016Assessment of In Vivo siRNA Delivery in Cancer Mouse Models.74Professor10Assistant Professor54InstructorCRISTINAIVANCRISTINA IVAN11810IVAN, CRISTINAAssistant ProfessorSHERRYWUSHERRY WU11822WU, SHERRYAssistant Professor26819345Zand B, Previs RA, Zacharias NM, Rupaimoole R, Mitamura T, Nagaraja AS, Guindani M, Dalton HJ, Yang L, Baddour J, Achreja A, Hu W, Pecot CV, Ivan C, Wu SY, McCullough CR, Gharpure KM, Shoshan E, Pradeep S, Mangala LS, Rodriguez-Aguayo C, Wang Y, Nick AM, Davies MA, Armaiz-Pena G, Liu J, Lutgendorf SK, Baggerly KA, Eli MB, Lopez-Berestein G, Nagrath D, Bhattacharya PK, Sood AKJournal of the National Cancer InstituteRole of Increased n-acetylaspartate Levels in Cancer. J Natl Cancer Inst. 2016 Jan 26; 108(6):djv426.J Natl Cancer Inst2016-01-26T00:00:002016Role of Increased n-acetylaspartate Levels in Cancer.27064283Haemmerle M, Bottsford-Miller J, Pradeep S, Taylor ML, Choi HJ, Hansen JM, Dalton HJ, Stone RL, Cho MS, Nick AM, Nagaraja AS, Gutschner T, Gharpure KM, Mangala LS, Rupaimoole R, Han HD, Zand B, Armaiz-Pena GN, Wu SY, Pecot CV, Burns AR, Lopez-Berestein G, Afshar-Kharghan V, Sood AKThe Journal of clinical investigationFAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. J Clin Invest. 2016 05 02; 126(5):1885-96.J Clin Invest2016-04-11T00:00:002016FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal.27300436Napoli M, Venkatanarayan A, Raulji P, Meyers BA, Norton W, Mangala LS, Sood AK, Rodriguez-Aguayo C, Lopez-Berestein G, Vin H, Duvic M, Tetzlaff MB, Curry JL, Rook AH, Abbas HA, Coarfa C, Gunaratne PH, Tsai KY, Flores ERCancer cell?Np63/DGCR8-Dependent MicroRNAs Mediate Therapeutic Efficacy of HDAC Inhibitors in Cancer. Cancer Cell. 2016 06 13; 29(6):874-888.Cancer Cell2016-06-13T00:00:002016?Np63/DGCR8-Dependent MicroRNAs Mediate Therapeutic Efficacy of HDAC Inhibitors in Cancer.18182619Gray MJ, Van Buren G, Dallas NA, Xia L, Wang X, Yang AD, Somcio RJ, Lin YG, Lim S, Fan F, Mangala LS, Arumugam T, Logsdon CD, Lopez-Berestein G, Sood AK, Ellis LMJournal of the National Cancer InstituteTherapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. J Natl Cancer Inst. 2008 Jan 16; 100(2):109-20.J Natl Cancer Inst2008-01-08T00:00:002008Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver.Authorship 373660618060038Fern?ndez A, Sanguino A, Peng Z, Ozturk E, Chen J, Crespo A, Wulf S, Shavrin A, Qin C, Ma J, Trent J, Lin Y, Han HD, Mangala LS, Bankson JA, Gelovani J, Samarel A, Bornmann W, Sood AK, Lopez-Berestein GThe Journal of clinical investigationAn anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. J Clin Invest. 2007 Dec; 117(12):4044-54.J Clin Invest2007-12-01T00:00:002007An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic.27829138Yang L, Achreja A, Yeung TL, Mangala LS, Jiang D, Han C, Baddour J, Marini JC, Ni J, Nakahara R, Wahlig S, Chiba L, Kim SH, Morse J, Pradeep S, Nagaraja AS, Haemmerle M, Kyunghee N, Derichsweiler M, Plackemeier T, Mercado-Uribe I, Lopez-Berestein G, Moss T, Ram PT, Liu J, Lu X, Mok SC, Sood AK, Nagrath DCell metabolismTargeting Stromal Glutamine Synthetase in Tumors Disrupts Tumor Microenvironment-Regulated Cancer Cell Growth. Cell Metab. 2016 11 08; 24(5):685-700.Cell Metab2016-11-08T00:00:002016Targeting Stromal Glutamine Synthetase in Tumors Disrupts Tumor Microenvironment-Regulated Cancer Cell Growth.20028751Vivas-Mejia P, Benito JM, Fernandez A, Han HD, Mangala L, Rodriguez-Aguayo C, Chavez-Reyes A, Lin YG, Carey MS, Nick AM, Stone RL, Kim HS, Claret FX, Bornmann W, Hennessy BT, Sanguino A, Peng Z, Sood AK, Lopez-Berestein GClinical cancer research : an official journal of the American Association for Cancer Researchc-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer. Clin Cancer Res. 2010 Jan 01; 16(1):184-94.Clin Cancer Res2009-12-22T00:00:002009c-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer.Authorship 841668Authorship 843813Authorship 845568Authorship 845745Authorship 845807Authorship 845986Authorship 848525Authorship 848652Authorship 848823Authorship 853860Authorship 854257Authorship 854704Authorship 855001Authorship 857105Authorship 857463Authorship 857480Authorship 858052Authorship 858888Authorship 860754Authorship 860783Authorship 864075Authorship 865834Authorship 866266Authorship 866762Authorship 866764Authorship 867439Authorship 867915Authorship 868115Cell MetabolismTargeting Stromal Glutamine Synthetase in Tumors Disrupts Tumor Microenvironment-Regulated Cancer Cell Growth. Cell Metabolism. 24:685-700.Targeting Stromal Glutamine Synthetase in Tumors Disrupts Tumor Microenvironment-Regulated Cancer Cell GrowthCancer CellErythropoietin Stimulates Tumor Growth via EphB4. Cancer Cell. 28:610-622.Erythropoietin Stimulates Tumor Growth via EphB4OncotargetChitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy. Oncotarget. 6:29161-29177.Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagyEuropean Food Research and TechnologyStructural studies of resistant starch derived from processed (autoclaved) rice. European Food Research and Technology. 209:38-42.Structural studies of resistant starch derived from processed (autoclaved) riceNature CommunicationsThe ZNF304-integrin axis protects against anoikis in cancer. Nature Communications. 6.The ZNF304-integrin axis protects against anoikis in cancerMolecular Cancer TherapeuticsTargeting c-MYC in platinum-resistant ovarian cancer. Molecular Cancer Therapeutics. 14:2260-2269.Targeting c-MYC in platinum-resistant ovarian cancerJournal of Molecular Catalysis B: EnzymaticRole of N- and C-terminal domains and non-homologous region in co-refolding of Thermotoga maritima β-glucosidase. Journal of Molecular Catalysis B: Enzymatic. 37:101-108.Role of N- and C-terminal domains and non-homologous region in co-refolding of Thermotoga maritima β-glucosidaseCancer CellSalt-Inducible Kinase 2 Couples Ovarian Cancer Cell Metabolism with Survival at the Adipocyte-Rich Metastatic Niche. Cancer Cell. Salt-Inducible Kinase 2 Couples Ovarian Cancer Cell Metabolism with Survival at the Adipocyte-Rich Metastatic NicheFood ChemistryResistant starch derived from processed ragi (finger millet, Eleusine coracana) flour. Food Chemistry. 64:475-479.Resistant starch derived from processed ragi (finger millet, Eleusine coracana) flourOncotargetReciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2. Oncotarget. 7:20825-20839.Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2Journal of Molecular Catalysis B: EnzymaticFusion of family VI cellulose binding domains to Bacillus halodurans xylanase increases its catalytic activity and substrate-binding capacity to insoluble xylan. Journal of Molecular Catalysis B: Enzymatic. 21:221-230.Fusion of family VI cellulose binding domains to Bacillus halodurans xylanase increases its catalytic activity and substrate-binding capacity to insoluble xylanEuropean Food Research and TechnologyResistant starch from differently processed rice and ragi (finger millet). European Food Research and Technology. 209:32-37.Resistant starch from differently processed rice and ragi (finger millet)Enzyme and Microbial TechnologyFragment complementation for the co-refolding of Thermotoga maritima β-glucosidase by gene splitting at non-homologous region. Enzyme and Microbial Technology. 40:732-739.Fragment complementation for the co-refolding of Thermotoga maritima β-glucosidase by gene splitting at non-homologous regionHepatologyYes-associated protein 1 and transcriptional coactivator with PDZ-binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma. Hepatology. 63:159-172.Yes-associated protein 1 and transcriptional coactivator with PDZ-binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinomaJournal of Clinical InvestigationErratum. Journal of Clinical Investigation. 123:4980.ErratumJournal of Clinical InvestigationErratum. Journal of Clinical Investigation. 123:5411.ErratumCancer CellCancer Cell. 29:874-888.Cancer CellCell ReportsRole of CTGF in Sensitivity to Hyperthermia in Ovarian and Uterine Cancers. Cell Reports. 17:1621-1631.Role of CTGF in Sensitivity to Hyperthermia in Ovarian and Uterine CancersFood ChemistryResistant starch from processed cereals. Food Chemistry. 64:391-396.Resistant starch from processed cerealsJournal of the National Cancer InstituteRole of Increased n-acetylaspartate Levels in Cancer. Journal of the National Cancer Institute. 108.Role of Increased n-acetylaspartate Levels in CancerOncogeneAntiangiogenic and tumour inhibitory effects of downregulating tumour endothelial FABP4. Oncogene. Antiangiogenic and tumour inhibitory effects of downregulating tumour endothelial FABP4OncogeneHypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression. Oncogene. Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progressionJournal of the Science of Food and AgricultureCell wall composition of 1B/1R translocation wheat grains. Journal of the Science of Food and Agriculture. 82:538-545.Cell wall composition of 1B/1R translocation wheat grainsAssessment of In vivo siRNA delivery in cancer mouse models. 189-197.Assessment of In vivo siRNA delivery in cancer mouse modelsNature CommunicationsErratum. Nature Communications. 4.ErratumCancer Biology and TherapyStress and the spread of ovarian cancer in mice. Cancer Biology and Therapy. 5:898.Stress and the spread of ovarian cancer in miceOncotargetTherapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer. Oncotarget. 7:15093-15104.Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancerJournal of Clinical InvestigationFAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. Journal of Clinical Investigation. 126:1885-1896.FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal28411194Wang Y, Xu X, Yu S, Jeong KJ, Zhou Z, Han L, Tsang YH, Li J, Chen H, Mangala LS, Yuan Y, Eterovic AK, Lu Y, Sood AK, Scott KL, Mills GB, Liang HGenome researchSystematic characterization of A-to-I RNA editing hotspots in microRNAs across human cancers. Genome Res. 2017 07; 27(7):1112-1125.Genome Res2017-04-14T00:00:002017Systematic characterization of A-to-I RNA editing hotspots in microRNAs across human cancers.29130936Wang S, Liang K, Hu Q, Li P, Song J, Yang Y, Yao J, Mangala LS, Li C, Yang W, Park PK, Hawke DH, Zhou J, Zhou Y, Xia W, Hung MC, Marks JR, Gallick GE, Lopez-Berestein G, Flores ER, Sood AK, Huang S, Yu D, Yang L, Lin CThe Journal of clinical investigationJAK2-binding long noncoding RNA promotes breast cancer brain metastasis. J Clin Invest. 2017 12 01; 127(12):4498-4515.J Clin Invest2017-11-13T00:00:002017JAK2-binding long noncoding RNA promotes breast cancer brain metastasis.Authorship 88732420Authorship 8885396Authorship 8887458Authorship 88882114Authorship 8891714Authorship 89020110D036104Chemicals & Drugs631320.893631Receptor, EphA2D034741Chemicals & Drugs77822160.625392RNA, Small InterferingD010051Disorders61946210.31574Ovarian NeoplasmsD009389Disorders52015470.585847Neovascularization, PathologicAuthorship 9049525Authorship 90784118Authorship 9085483Authorship 9099771Authorship 9105463Authorship 9131408Authorship 9144602Authorship 9184948Authorship 91905714Authorship 9197043Authorship 91974624Authorship 9203153Authorship 9209858Authorship 9209901Authorship 9224293Authorship 92354111Authorship 9249728Authorship 9251559Authorship 92592618Authorship 9260552Authorship 92735111Authorship 9275416Authorship 9299175Authorship 9313917D035683Chemicals & Drugs75129430.373492MicroRNAsAuthorship 9342724Authorship 93603713Authorship 9385918Authorship 939385926959114Rytelewski M, Maleki Vareki S, Mangala LS, Romanow L, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Figueredo R, Ferguson PJ, Vincent M, Sood AK, Koropatnick JDOncotargetReciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2. Oncotarget. 2016 Apr 12; 7(15):20825-39.Oncotarget2016-04-12T00:00:002016Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2.26918603Dwivedi SK, Mustafi SB, Mangala LS, Jiang D, Pradeep S, Rodriguez-Aguayo C, Ling H, Ivan C, Mukherjee P, Calin GA, Lopez-Berestein G, Sood AK, Bhattacharya ROncotargetTherapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer. Oncotarget. 2016 Mar 22; 7(12):15093-104.Oncotarget2016-03-22T00:00:002016Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer.27478041Miranda F, Mannion D, Liu S, Zheng Y, Mangala LS, Redondo C, Herrero-Gonzalez S, Xu R, Taylor C, Chedom DF, Carrami EM, Albukhari A, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Salah E, Abdul Azeez KR, Elkins JM, Campo L, Myers KA, Klotz D, Bivona S, Dhar S, Bast RC, Saya H, Choi HG, Gray NS, Fischer R, Kessler BM, Yau C, Sood AK, Motohara T, Knapp S, Ahmed AACancer cellSalt-Inducible Kinase 2 Couples Ovarian Cancer Cell Metabolism with Survival at the Adipocyte-Rich Metastatic Niche. Cancer Cell. 2016 08 08; 30(2):273-289.Cancer Cell2016-07-28T00:00:002016Salt-Inducible Kinase 2 Couples Ovarian Cancer Cell Metabolism with Survival at the Adipocyte-Rich Metastatic Niche.27992857Moruno-Manchon JF, Uzor NE, Kesler SR, Wefel JS, Townley DM, Nagaraja AS, Pradeep S, Mangala LS, Sood AK, Tsvetkov ASAgingTFEB ameliorates the impairment of the autophagy-lysosome pathway in neurons induced by doxorubicin. Aging (Albany NY). 2016 12 16; 8(12):3507-3519.Aging (Albany NY)2016-12-16T00:00:002016TFEB ameliorates the impairment of the autophagy-lysosome pathway in neurons induced by doxorubicin.27806300Hatakeyama H, Wu SY, Lyons YA, Pradeep S, Wang W, Huang Q, Court KA, Liu T, Nie S, Rodriguez-Aguayo C, Shen F, Huang Y, Hisamatsu T, Mitamura T, Jennings N, Shim J, Dorniak PL, Mangala LS, Petrillo M, Petyuk VA, Schepmoes AA, Shukla AK, Torres-Lugo M, Lee JS, Rodland KD, Fagotti A, Lopez-Berestein G, Li C, Sood AKCell reportsRole of CTGF in Sensitivity to Hyperthermia in Ovarian and Uterine Cancers. Cell Rep. 2016 11 01; 17(6):1621-1631.Cell Rep2016-11-01T00:00:002016Role of CTGF in Sensitivity to Hyperthermia in Ovarian and Uterine Cancers.27777972Mangala LS, Wang H, Jiang D, Wu SY, Somasunderam A, Volk DE, Lokesh GLR, Li X, Pradeep S, Yang X, Haemmerle M, Rodriguez-Aguayo C, Nagaraja AS, Rupaimoole R, Bayraktar E, Bayraktar R, Li L, Tanaka T, Hu W, Ivan C, Gharpure KM, McGuire MH, Thiviyanathan V, Zhang X, Maiti SN, Bulayeva N, Choi HJ, Dorniak PL, Cooper LJ, Rosenblatt KP, Lopez-Berestein G, Gorenstein DG, Sood AKJCI insightImproving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy. JCI Insight. 2016 Oct 20; 1(17):e87754.JCI Insight2016-10-20T00:00:002016Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy.28376174Previs RA, Armaiz-Pena GN, Ivan C, Dalton HJ, Rupaimoole R, Hansen JM, Lyons Y, Huang J, Haemmerle M, Wagner MJ, Gharpure KM, Nagaraja AS, Filant J, McGuire MH, Noh K, Dorniak PL, Linesch SL, Mangala LS, Pradeep S, Wu SY, Sood AKJournal of the National Cancer InstituteRole of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies. J Natl Cancer Inst. 2017 07 01; 109(7).J Natl Cancer Inst2017-07-01T00:00:002017Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies.28423708Rabinowicz N, Mangala LS, Brown KR, Checa-Rodriguez C, Castiel A, Moskovich O, Zarfati G, Trakhtenbrot L, Levy-Barda A, Jiang D, Rodriguez-Aguayo C, Pradeep S, van Praag Y, Lopez-Berestein G, David A, Novikov I, Huertas P, Rottapel R, Sood AK, Izraeli SOncotargetTargeting the centriolar replication factor STIL synergizes with DNA damaging agents for treatment of ovarian cancer. Oncotarget. 2017 Apr 18; 8(16):27380-27392.Oncotarget2017-04-18T00:00:002017Targeting the centriolar replication factor STIL synergizes with DNA damaging agents for treatment of ovarian cancer.28730442Denizli M, Aslan B, Mangala LS, Jiang D, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AKMethods in molecular biology (Clifton, N.J.)Chitosan Nanoparticles for miRNA Delivery. Methods Mol Biol. 2017; 1632:219-230.Methods Mol Biol2017-01-01T00:00:002017Chitosan Nanoparticles for miRNA Delivery.28855350Dalton HJ, Pradeep S, McGuire M, Hailemichael Y, Ma S, Lyons Y, Armaiz-Pena GN, Previs RA, Hansen JM, Rupaimoole R, Gonzalez-Villasana V, Cho MS, Wu SY, Mangala LS, Jennings NB, Hu W, Langley R, Mu H, Andreeff M, Bar-Eli M, Overwijk W, Ram P, Lopez-Berestein G, Coleman RL, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchMacrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression. Clin Cancer Res. 2017 Nov 15; 23(22):7034-7046.Clin Cancer Res2017-08-29T00:00:002017Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression.29180229Moruno-Manchon JF, Uzor NE, Kesler SR, Wefel JS, Townley DM, Nagaraja AS, Pradeep S, Mangala LS, Sood AK, Tsvetkov ASMolecular and cellular neurosciencesPeroxisomes contribute to oxidative stress in neurons during doxorubicin-based chemotherapy. Mol Cell Neurosci. 2018 01; 86:65-71.Mol Cell Neurosci2017-11-24T00:00:002017Peroxisomes contribute to oxidative stress in neurons during doxorubicin-based chemotherapy.29180471Lu Y, Hu Z, Mangala LS, Stine ZE, Hu X, Jiang D, Xiang Y, Zhang Y, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, DeMarzo AM, Sood AK, Zhang L, Dang CVCancer researchMYC Targeted Long Noncoding RNA DANCR Promotes Cancer in Part by Reducing p21 Levels. Cancer Res. 2018 01 01; 78(1):64-74.Cancer Res2017-11-27T00:00:002017MYC Targeted Long Noncoding RNA DANCR Promotes Cancer in Part by Reducing p21 Levels.29237804Huang Y, Hu W, Huang J, Shen F, Sun Y, Ivan C, Pradeep S, Dood R, Haemmerle M, Jiang D, Mangala LS, Noh K, Hansen JM, Dalton HJ, Previs RA, Nagaraja AS, McGuire M, Jennings NB, Broaddus R, Coleman RL, Sood AKMolecular cancer therapeuticsInhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer. Mol Cancer Ther. 2018 02; 17(2):464-473.Mol Cancer Ther2017-12-13T00:00:002017Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer.28827520Haemmerle M, Taylor ML, Gutschner T, Pradeep S, Cho MS, Sheng J, Lyons YM, Nagaraja AS, Dood RL, Wen Y, Mangala LS, Hansen JM, Rupaimoole R, Gharpure KM, Rodriguez-Aguayo C, Yim SY, Lee JS, Ivan C, Hu W, Lopez-Berestein G, Wong ST, Karlan BY, Levine DA, Liu J, Afshar-Kharghan V, Sood AKNature communicationsPlatelets reduce anoikis and promote metastasis by activating YAP1 signaling. Nat Commun. 2017 08 21; 8(1):310.Nat Commun2017-08-21T00:00:002017Platelets reduce anoikis and promote metastasis by activating YAP1 signaling.28814667Nagaraja AS, Dood RL, Armaiz-Pena G, Kang Y, Wu SY, Allen JK, Jennings NB, Mangala LS, Pradeep S, Lyons Y, Haemmerle M, Gharpure KM, Sadaoui NC, Rodriguez-Aguayo C, Ivan C, Wang Y, Baggerly K, Ram P, Lopez-Berestein G, Liu J, Mok SC, Cohen L, Lutgendorf SK, Cole SW, Sood AKJCI insightAdrenergic-mediated increases in INHBA drive CAF phenotype and collagens. JCI Insight. 2017 Aug 17; 2(16).JCI Insight2017-08-17T00:00:002017Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens.29251630Leung CS, Yeung TL, Yip KP, Wong KK, Ho SY, Mangala LS, Sood AK, Lopez-Berestein G, Sheng J, Wong ST, Birrer MJ, Mok SCThe Journal of clinical investigationCancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance. J Clin Invest. 2018 02 01; 128(2):589-606.J Clin Invest2017-12-18T00:00:002017Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance.29396402Zheng Y, Sethi R, Mangala LS, Taylor C, Goldsmith J, Wang M, Masuda K, Carrami EM, Mannion D, Miranda F, Herrero-Gonzalez S, Hellner K, Chen F, Alsaadi A, Albukhari A, Fotso DC, Yau C, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Knapp S, Gray NS, Campo L, Myers KA, Dhar S, Ferguson D, Bast RC, Sood AK, von Delft F, Ahmed AANature communicationsTuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation. Nat Commun. 2018 02 02; 9(1):476.Nat Commun2018-02-02T00:00:002018Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation.29809169Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, Langley RR, Jennings NB, Ivan C, Coffin JE, Armaiz GN, Bottsford-Miller J, Kim SB, Halleck MS, Hendrix MJ, Bornman W, Bar-Eli M, Lee JS, Siddik ZH, Lopez-Berestein G, Sood AKThe Journal of clinical investigationATP11B mediates platinum resistance in ovarian cancer. J Clin Invest. 2018 07 02; 128(7):3199.J Clin Invest2018-05-29T00:00:002018ATP11B mediates platinum resistance in ovarian cancer.29661830Allen JK, Armaiz-Pena GN, Nagaraja AS, Sadaoui NC, Ortiz T, Dood R, Ozcan M, Herder DM, Haemmerle M, Gharpure KM, Rupaimoole R, Previs RA, Wu SY, Pradeep S, Xu X, Han HD, Zand B, Dalton HJ, Taylor M, Hu W, Bottsford-Miller J, Moreno-Smith M, Kang Y, Mangala LS, Rodriguez-Aguayo C, Sehgal V, Spaeth EL, Ram PT, Wong STC, Marini FC, Lopez-Berestein G, Cole SW, Lutgendorf SK, De Biasi M, Sood AKCancer researchSustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction. Cancer Res. 2018 06 15; 78(12):3233-3242.Cancer Res2018-04-16T00:00:002018Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction.29212026Noh K, Mangala LS, Han HD, Zhang N, Pradeep S, Wu SY, Ma S, Mora E, Rupaimoole R, Jiang D, Wen Y, Shahzad MMK, Lyons Y, Cho M, Hu W, Nagaraja AS, Haemmerle M, Mak CSL, Chen X, Gharpure KM, Deng H, Xiong W, Kingsley CV, Liu J, Jennings N, Birrer MJ, Bouchard RR, Lopez-Berestein G, Coleman RL, An Z, Sood AKCell reportsDifferential Effects of EGFL6 on Tumor versus Wound Angiogenesis. Cell Rep. 2017 Dec 05; 21(10):2785-2795.Cell Rep2017-12-05T00:00:002017Differential Effects of EGFL6 on Tumor versus Wound Angiogenesis.29861857Gharpure KM, Lara OD, Wen Y, Pradeep S, LaFargue C, Ivan C, Rupaimoole R, Hu W, Mangala LS, Wu SY, Nagaraja AS, Baggerly K, Sood AKOncotargetADH1B promotes mesothelial clearance and ovarian cancer infiltration. Oncotarget. 2018 May 18; 9(38):25115-25126.Oncotarget2018-05-18T00:00:002018ADH1B promotes mesothelial clearance and ovarian cancer infiltration.30084832Yang H, Mao W, Rodriguez-Aguayo C, Mangala LS, Bartholomeusz G, Iles LR, Jennings NB, Ahmed AA, Sood AK, Lopez-Berestein G, Lu Z, Bast RCClinical cancer research : an official journal of the American Association for Cancer ResearchPaclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability. Clin Cancer Res. 2018 10 15; 24(20):5072-5084.Clin Cancer Res2018-07-03T00:00:002018Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability.29889660Nagaraja AS, Dood RL, Armaiz-Pena G, Kang Y, Wu SY, Allen JK, Jennings NB, Mangala LS, Pradeep S, Lyons Y, Haemmerle M, Gharpure KM, Sadaoui NC, Rodriguez-Aguayo C, Ivan C, Wang Y, Baggerly K, Ram P, Lopez-Berestein G, Liu J, Mok SC, Cohen L, Lutgendorf SK, Cole SW, Sood AKJCI insightAdrenergic-mediated increases in INHBA drive CAF phenotype and collagens. JCI Insight. 2018 Jun 07; 3(11).JCI Insight2018-06-07T00:00:002018Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens.29889661Mangala LS, Wang H, Jiang D, Wu SY, Somasunderam A, Volk DE, Lokesh GLR, Li X, Pradeep S, Yang X, Haemmerle M, Rodriguez-Aguayo C, Nagaraja AS, Rupaimoole R, Bayraktar E, Bayraktar R, Li L, Tanaka T, Hu W, Ivan C, Gharpure KM, McGuire MH, Thiviyanathan V, Zhang X, Maiti SN, Bulayeva N, Choi HJ, Dorniak PL, Cooper LJ, Rosenblatt KP, Lopez-Berestein G, Gorenstein DG, Sood AKJCI insightImproving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy. JCI Insight. 2018 06 07; 3(11).JCI Insight2018-06-07T00:00:002018Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy.30050129Gharpure KM, Pradeep S, Sans M, Rupaimoole R, Ivan C, Wu SY, Bayraktar E, Nagaraja AS, Mangala LS, Zhang X, Haemmerle M, Hu W, Rodriguez-Aguayo C, McGuire M, Mak CSL, Chen X, Tran MA, Villar-Prados A, Pena GA, Kondetimmanahalli R, Nini R, Koppula P, Ram P, Liu J, Lopez-Berestein G, Baggerly K, S Eberlin L, Sood AKNature communicationsFABP4 as a key determinant of metastatic potential of ovarian cancer. Nat Commun. 2018 07 26; 9(1):2923.Nat Commun2018-07-26T00:00:002018FABP4 as a key determinant of metastatic potential of ovarian cancer.30655206Rodriguez-Aguayo C, Bayraktar E, Ivan C, Aslan B, Mai J, He G, Mangala LS, Jiang D, Nagaraja AS, Ozpolat B, Chavez-Reyes A, Ferrari M, Mitra R, Siddik ZH, Shen H, Yang X, Sood AK, Lopez-Berestein GEBioMedicinePTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis. EBioMedicine. 2019 Feb; 40:290-304.EBioMedicine2019-01-14T00:00:002019PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis.30291236Inoue K, Deng Z, Chen Y, Giannopoulou E, Xu R, Gong S, Greenblatt MB, Mangala LS, Lopez-Berestein G, Kirsch DG, Sood AK, Zhao L, Zhao BNature communicationsBone protection by inhibition of microRNA-182. Nat Commun. 2018 10 05; 9(1):4108.Nat Commun2018-10-05T00:00:002018Bone protection by inhibition of microRNA-182.30305341Hisamatsu T, McGuire M, Wu SY, Rupaimoole R, Pradeep S, Bayraktar E, Noh K, Hu W, Hansen JM, Lyons Y, Gharpure KM, Nagaraja AS, Mangala LS, Mitamura T, Rodriguez-Aguayo C, Eun YG, Rose J, Bartholomeusz G, Ivan C, Lee JS, Matsuo K, Frumovitz M, Wong KK, Lopez-Berestein G, Sood AKMolecular cancer therapeuticsPRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer. Mol Cancer Ther. 2019 01; 18(1):162-172.Mol Cancer Ther2018-10-10T00:00:002018PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer.Authorship 942227229243000Chen X, Mangala LS, Rodriguez-Aguayo C, Kong X, Lopez-Berestein G, Sood AKCancer metastasis reviewsRNA interference-based therapy and its delivery systems. Cancer Metastasis Rev. 2018 03; 37(1):107-124.Cancer Metastasis Rev2018-03-01T00:00:002018RNA interference-based therapy and its delivery systems.Authorship 9430098Authorship 943568630918328Azam SH, Porrello A, Harrison EB, Leslie PL, Liu X, Waugh TA, Belanger A, Mangala LS, Lopez-Berestein G, Wilson HL, McCann JV, Kim WY, Sood AK, Liu J, Dudley AC, Pecot CVOncogeneQuaking orchestrates a post-transcriptional regulatory network of endothelial cell cycle progression critical to angiogenesis and metastasis. Oncogene. 2019 06; 38(26):5191-5210.Oncogene2019-03-27T00:00:002019Quaking orchestrates a post-transcriptional regulatory network of endothelial cell cycle progression critical to angiogenesis and metastasis.30926640Ma S, Pradeep S, Villar-Prados A, Wen Y, Bayraktar E, Mangala LS, Kim MS, Wu SY, Hu W, Rodriguez-Aguayo C, Leuschner C, Liang X, Ram PT, Schlacher K, Coleman RL, Sood AKMolecular cancer therapeuticsGnRH-R-Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP Inhibition. Mol Cancer Ther. 2019 05; 18(5):969-979.Mol Cancer Ther2019-03-29T00:00:002019GnRH-R-Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP Inhibition.Authorship 9458501431012964Gunaratne PH, Pan Y, Rao AK, Lin C, Hernandez-Herrera A, Liang K, Rait AS, Venkatanarayan A, Benham AL, Rubab F, Kim SS, Rajapakshe K, Chan CK, Mangala LS, Lopez-Berestein G, Sood AK, Rowat AC, Coarfa C, Pirollo KF, Flores ER, Chang EHCancerActivating p53 family member TAp63: A novel therapeutic strategy for targeting p53-altered tumors. Cancer. 2019 07 15; 125(14):2409-2422.Cancer2019-04-23T00:00:002019Activating p53 family member TAp63: A novel therapeutic strategy for targeting p53-altered tumors.Authorship 947599931127195Krzeszinski JY, Wei W, Huynh H, Jin Z, Wang X, Chang TC, Xie XJ, He L, Mangala LS, Lopez-Berestein G, Sood AK, Mendell JT, Wan YNatureAuthor Correction: miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2. Nature. 2019 Jun; 570(7761):E51.Nature2019-06-01T00:00:002019Author Correction: miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2.Authorship 951600231289363Chen X, Mangala LS, Mooberry L, Bayraktar E, Dasari SK, Ma S, Ivan C, Court KA, Rodriguez-Aguayo C, Bayraktar R, Raut S, Sabnis N, Kong X, Yang X, Lopez-Berestein G, Lacko AG, Sood AKOncogeneIdentifying and targeting angiogenesis-related microRNAs in ovarian cancer. Oncogene. 2019 08; 38(33):6095-6108.Oncogene2019-07-09T00:00:002019Identifying and targeting angiogenesis-related microRNAs in ovarian cancer.Authorship 960471631682236Xu X, Wang Y, Mojumdar K, Zhou Z, Jeong KJ, Mangala LS, Yu S, Tsang YH, Rodriguez-Aguayo C, Lu Y, Lopez-Berestein G, Sood AK, Mills GB, Liang HThe Journal of clinical investigationA-to-I-edited miRNA-379-5p inhibits cancer cell proliferation through CD97-induced apoptosis. J Clin Invest. 2019 12 02; 129(12):5343-5356.J Clin Invest2019-12-02T00:00:002019A-to-I-edited miRNA-379-5p inhibits cancer cell proliferation through CD97-induced apoptosis.Authorship 9746801131875548Parashar D, Geethadevi A, Aure MR, Mishra J, George J, Chen C, Mishra MK, Tahiri A, Zhao W, Nair B, Lu Y, Mangala LS, Rodriguez-Aguayo C, Lopez-Berestein G, Camara AKS, Liang M, Rader JS, Ramchandran R, You M, Sood AK, Kristensen VN, Mills GB, Pradeep S, Chaluvally-Raghavan PCell reportsmiRNA551b-3p Activates an Oncostatin Signaling Module for the Progression of Triple-Negative Breast Cancer. Cell Rep. 2019 12 24; 29(13):4389-4406.e10.Cell Rep2019-12-24T00:00:002019miRNA551b-3p Activates an Oncostatin Signaling Module for the Progression of Triple-Negative Breast Cancer.Authorship 9908299Authorship 9909511632493919Rupaimoole R, Wu SY, Pradeep S, Ivan C, Pecot CV, Gharpure KM, Nagaraja AS, Armaiz-Pena GN, McGuire M, Zand B, Dalton HJ, Filant J, Miller JB, Lu C, Sadaoui NC, Mangala LS, Taylor M, van den Beucken T, Koch E, Rodriguez-Aguayo C, Huang L, Bar-Eli M, Wouters BG, Radovich M, Ivan M, Calin GA, Zhang W, Lopez-Berestein G, Sood AKNature communicationsAuthor Correction: Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression. Nat Commun. 2020 06 03; 11(1):2867.Nat Commun2020-06-03T00:00:002020Author Correction: Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression.32483375Krzeszinski JY, Wei W, Huynh H, Jin Z, Wang X, Chang TC, Xie XJ, He L, Mangala LS, Lopez-Berestein G, Sood AK, Mendell JT, Wan YNatureRetraction Note: miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2. Nature. 2020 06; 582(7810):134.Nature2020-06-01T00:00:002020Retraction Note: miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2.Authorship 993608632623336Li Y, Yang S, Sadaoui NC, Hu W, Dasari SK, Mangala LS, Sun Y, Zhao S, Wang L, Liu Y, Ramondetta LM, Li K, Lu C, Kang Y, Cole SW, Lutgendorf SK, Sood AKiScienceSustained Adrenergic Activation of YAP1 Induces Anoikis Resistance in Cervical Cancer Cells. iScience. 2020 Jul 24; 23(7):101289.iScience2020-06-20T00:00:002020Sustained Adrenergic Activation of YAP1 Induces Anoikis Resistance in Cervical Cancer Cells.Authorship 996119832754300Lara OD, Bayraktar E, Amero P, Ma S, Ivan C, Hu W, Wang Y, Mangala LS, Dutta P, Bhattacharya P, Ashizawa AT, Lopez-Berestein G, Rodriguez-Aguayo C, Sood AKOncotargetTherapeutic efficacy of liposomal Grb2 antisense oligodeoxynucleotide (L-Grb2) in preclinical models of ovarian and uterine cancer. Oncotarget. 2020 Jul 21; 11(29):2819-2833.Oncotarget2020-07-21T00:00:002020Therapeutic efficacy of liposomal Grb2 antisense oligodeoxynucleotide (L-Grb2) in preclinical models of ovarian and uterine cancer.Authorship 999641432934031Yang H, Mao W, Rodriguez-Aguayo C, Mangala LS, Bartholomeusz G, Iles LR, Jennings NB, Ahmed AA, Sood AK, Lopez-Berestein G, Lu Z, Bast RCClinical cancer research : an official journal of the American Association for Cancer ResearchCorrection: Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability. Clin Cancer Res. 2020 09 15; 26(18):5050.Clin Cancer Res2020-09-15T00:00:002020Correction: Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability.Authorship 10044881333149280Noh K, Bach DH, Choi HJ, Kim MS, Wu SY, Pradeep S, Ivan C, Cho MS, Bayraktar E, Rodriguez-Aguayo C, Dasari SK, Stur E, Mangala LS, Lopez-Berestein G, Sood AKOncogeneThe hidden role of paxillin: localization to nucleus promotes tumor angiogenesis. Oncogene. 2021 01; 40(2):384-395.Oncogene2020-11-04T00:00:002020The hidden role of paxillin: localization to nucleus promotes tumor angiogenesis.Authorship 1011106333567287Ma S, McGuire MH, Mangala LS, Lee S, Stur E, Hu W, Bayraktar E, Villar-Prados A, Ivan C, Wu SY, Yokoi A, Dasari SK, Jennings NB, Liu J, Lopez-Berestein G, Ram P, Sood AKCell reportsGain-of-function p53 protein transferred via small extracellular vesicles promotes conversion of fibroblasts to a cancer-associated phenotype. Cell Rep. 2021 02 09; 34(6):108726.Cell Rep2021-02-09T00:00:002021Gain-of-function p53 protein transferred via small extracellular vesicles promotes conversion of fibroblasts to a cancer-associated phenotype.Authorship 10156225Authorship 10156551Authorship 1015660833792569Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, Langley RR, Jennings NB, Ivan C, Coffin JE, Armaiz GN, Bottsford-Miller J, Kim SB, Halleck MS, Hendrix MJ, Bornman W, Bar-Eli M, Lee JS, Siddik ZH, Lopez-Berestein G, Sood AKThe Journal of clinical investigationATP11B mediates platinum resistance in ovarian cancer. J Clin Invest. 2021 04 01; 131(7).J Clin Invest2021-04-01T00:00:002021ATP11B mediates platinum resistance in ovarian cancer.33793423Mangala LS, Wang H, Jiang D, Wu SY, Somasunderam A, Volk DE, Lokesh GLR, Li X, Pradeep S, Yang X, Haemmerle M, Rodriguez-Aguayo C, Nagaraja AS, Rupaimoole R, Bayraktar E, Bayraktar R, Li L, Tanaka T, Hu W, Ivan C, Gharpure KM, McGuire MH, Thiviyanathan V, Zhang X, Maiti SN, Bulayeva N, Choi HJ, Dorniak PL, Cooper LJ, Rosenblatt KP, Lopez-Berestein G, Gorenstein DG, Sood AKJCI insightImproving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy. JCI Insight. 2021 04 08; 6(7).JCI Insight2021-04-08T00:00:002021Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy.33793425Nagaraja AS, Dood RL, Armaiz-Pena G, Kang Y, Wu SY, Allen JK, Jennings NB, Mangala LS, Pradeep S, Lyons Y, Haemmerle M, Gharpure KM, Sadaoui NC, Rodriguez-Aguayo C, Ivan C, Wang Y, Baggerly K, Ram P, Lopez-Berestein G, Liu J, Mok SC, Cohen L, Lutgendorf SK, Cole SW, Sood AKJCI insightAdrenergic-mediated increases in INHBA drive CAF phenotype and collagens. JCI Insight. 2021 04 08; 6(7).JCI Insight2021-04-08T00:00:002021Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens.Authorship 1017418733931674Wagner MJ, Lyons YA, Siedel JH, Dood R, Nagaraja AS, Haemmerle M, Mangala LS, Chanana P, Lazar AJ, Wang WL, Ravi V, Holland EC, Sood AKScientific reportsCombined VEGFR and MAPK pathway inhibition in angiosarcoma. Sci Rep. 2021 04 30; 11(1):9362.Sci Rep2021-04-30T00:00:002021Combined VEGFR and MAPK pathway inhibition in angiosarcoma.Authorship 1020086434065218Gao C, Jin G, Forbes E, Mangala LS, Wang Y, Rodriguez-Aguayo C, Amero P, Bayraktar E, Yan Y, Lopez-Berestein G, Broaddus RR, Sood AK, Xue F, Zhang WCancersInactivating Mutations of the IK Gene Weaken Ku80/Ku70-Mediated DNA Repair and Sensitize Endometrial Cancer to Chemotherapy. Cancers (Basel). 2021 May 20; 13(10).Cancers (Basel)2021-05-20T00:00:002021Inactivating Mutations of the IK Gene Weaken Ku80/Ku70-Mediated DNA Repair and Sensitize Endometrial Cancer to Chemotherapy.Authorship 10267435Authorship 10271007Authorship 102710312Authorship 10271052Authorship 1027109134341056Moreno-Smith M, Lu C, Shahzad MMK, Pena GNA, Allen JK, Stone RL, Mangala LS, Han HD, Kim HS, Farley D, Berestein GL, Cole SW, Lutgendorf SK, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchEditor's Note: Dopamine Blocks Stress-mediated Ovarian Carcinoma Growth. Clin Cancer Res. 2021 08 01; 27(15):4451.Clin Cancer Res2021-08-01T00:00:002021Editor's Note: Dopamine Blocks Stress-mediated Ovarian Carcinoma Growth.34341057Kim HS, Han HD, Armaiz-Pena GN, Stone RL, Nam EJ, Lee JW, Shahzad MMK, Nick AM, Lee SJ, Roh JW, Nishimura M, Mangala LS, Bottsford-Miller J, Gallick GE, Lopez-Berestein G, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchEditor's Note: Functional Roles of Src and Fgr in Ovarian Carcinoma. Clin Cancer Res. 2021 08 01; 27(15):4452.Clin Cancer Res2021-08-01T00:00:002021Editor's Note: Functional Roles of Src and Fgr in Ovarian Carcinoma.34341058Han HD, Mangala LS, Lee JW, Shahzad MMK, Kim HS, Shen D, Nam EJ, Mora EM, Stone RL, Lu C, Lee SJ, Roh JW, Nick AM, Lopez-Berestein G, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchEditor's Note: Targeted Gene Silencing Using RGD-Labeled Chitosan Nanoparticles. Clin Cancer Res. 2021 08 01; 27(15):4453.Clin Cancer Res2021-08-01T00:00:002021Editor's Note: Targeted Gene Silencing Using RGD-Labeled Chitosan Nanoparticles.34341059Mangala LS, Zuzel V, Schmandt R, Leshane ES, Halder JB, Armaiz-Pena GN, Spannuth WA, Tanaka T, Shahzad MMK, Lin YG, Nick AM, Danes CG, Lee JW, Jennings NB, Vivas-Mejia PE, Wolf JK, Coleman RL, Siddik ZH, Lopez-Berestein G, Lutsenko S, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchEditor's Note: Therapeutic Targeting of ATP7B in Ovarian Carcinoma. Clin Cancer Res. 2021 08 01; 27(15):4454.Clin Cancer Res2021-08-01T00:00:002021Editor's Note: Therapeutic Targeting of ATP7B in Ovarian Carcinoma.34348992McGuire MH, Dasari SK, Yao H, Wen Y, Mangala LS, Bayraktar E, Ma W, Ivan C, Shoshan E, Wu SY, Jonasch E, Bar-Eli M, Wang J, Baggerly KA, Sood AKMolecular cancer research : MCRGene Body Methylation of the Lymphocyte-Specific Gene CARD11 Results in Its Overexpression and Regulates Cancer mTOR Signaling. Mol Cancer Res. 2021 11; 19(11):1917-1928.Mol Cancer Res2021-08-04T00:00:002021Gene Body Methylation of the Lymphocyte-Specific Gene CARD11 Results in Its Overexpression and Regulates Cancer mTOR Signaling.Authorship 10278016Authorship 10279662Authorship 1028095134407412Ma S, Mangala LS, Hu W, Bayaktar E, Yokoi A, Hu W, Pradeep S, Lee S, Piehowski PD, Villar-Prados A, Wu SY, McGuire MH, Lara OD, Rodriguez-Aguayo C, LaFargue CJ, Jennings NB, Rodland KD, Liu T, Kundra V, Ram PT, Ramakrishnan S, Lopez-Berestein G, Coleman RL, Sood AKCell reportsCD63-mediated cloaking of VEGF in small extracellular vesicles contributes to anti-VEGF therapy resistance. Cell Rep. 2021 08 17; 36(7):109549.Cell Rep2021-08-17T00:00:002021CD63-mediated cloaking of VEGF in small extracellular vesicles contributes to anti-VEGF therapy resistance.34417750Mangala LS, Rodriguez-Aguayo C, Bayraktar E, Jennings NB, Lopez-Berestein G, Sood AKMethods in molecular biology (Clifton, N.J.)Assessment of In Vivo siRNA Delivery in Cancer Mouse Models. Methods Mol Biol. 2021; 2372:157-168.Methods Mol Biol2021-01-01T00:00:002021Assessment of In Vivo siRNA Delivery in Cancer Mouse Models.34391578Wu Y, Huang J, Ivan C, Sun Y, Ma S, Mangala LS, Fellman BM, Urbauer DL, Jennings NB, Ram P, Coleman RL, Hu W, Sood AKGynecologic oncologyMEK inhibition overcomes resistance to EphA2-targeted therapy in uterine cancer. Gynecol Oncol. 2021 10; 163(1):181-190.Gynecol Oncol2021-08-11T00:00:002021MEK inhibition overcomes resistance to EphA2-targeted therapy in uterine cancer.Authorship 10331181334799731Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, Jennings NB, Armaiz-Pena G, Bankson JA, Ravoori M, Merritt WM, Lin YG, Mangala LS, Kim TJ, Coleman RL, Landen CN, Li Y, Felix E, Sanguino AM, Newman RA, Lloyd M, Gershenson DM, Kundra V, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AKNature medicineAuthor Correction: Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med. 2021 Dec; 27(12):2246.Nat Med2021-12-01T00:00:002021Author Correction: Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma.Authorship 1039131935094142Wu Y, Jennings NB, Sun Y, Dasari SK, Bayraktar E, Corvigno S, Stur E, Glassman D, Mangala LS, Lankenau Ahumada A, Westin SN, Sood AK, Hu WJournal of cancer research and clinical oncologyTargeting CCR2+ macrophages with BET inhibitor overcomes adaptive resistance to anti-VEGF therapy in ovarian cancer. J Cancer Res Clin Oncol. 2022 Apr; 148(4):803-821.J Cancer Res Clin Oncol2022-01-30T00:00:002022Targeting CCR2+ macrophages with BET inhibitor overcomes adaptive resistance to anti-VEGF therapy in ovarian cancer.23360994Armaiz-Pena GN, Allen JK, Cruz A, Stone RL, Nick AM, Lin YG, Han LY, Mangala LS, Villares GJ, Vivas-Mejia P, Rodriguez-Aguayo C, Nagaraja AS, Gharpure KM, Wu Z, English RD, Soman KV, Shahzad MM, Shazhad MM, Zigler M, Deavers MT, Zien A, Soldatos TG, Jackson DB, Wiktorowicz JE, Torres-Lugo M, Young T, De Geest K, Gallick GE, Bar-Eli M, Lopez-Berestein G, Cole SW, Lopez GE, Lutgendorf SK, Sood AKNature communicationsSrc activation by ?-adrenoreceptors is a key switch for tumour metastasis. Nat Commun. 2013; 4:1403.Nat Commun2013-01-01T00:00:002013Src activation by ?-adrenoreceptors is a key switch for tumour metastasis.Authorship 1047440335688808Zheng Y, Sethi R, Mangala LS, Taylor C, Goldsmith J, Wang M, Masuda K, Carrami EM, Mannion D, Miranda F, Herrero-Gonzalez S, Hellner K, Chen F, Alsaadi A, Albukhari A, Fotso DC, Yau C, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Knapp S, Gray NS, Campo L, Myers KA, Dhar S, Ferguson D, Bast RC, Sood AK, von Delft F, Ahmed AANature communicationsAuthor Correction: Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation. Nat Commun. 2022 Jun 10; 13(1):3352.Nat Commun2022-06-10T00:00:002022Author Correction: Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation.Authorship 10602647Authorship 10573193Authorship 1061084535965413Jensen DM, Han P, Mangala LS, Lopez-Berestein G, Sood AK, Liu J, Kriegel AJ, Usa K, Widlansky ME, Liang MMolecular therapy : the journal of the American Society of Gene TherapyBroad-acting therapeutic effects of miR-29b-chitosan on hypertension and diabetic complications. Mol Ther. 2022 11 02; 30(11):3462-3476.Mol Ther2022-08-13T00:00:002022Broad-acting therapeutic effects of miR-29b-chitosan on hypertension and diabetic complications.35914489Rodriguez-Aguayo C, Bayraktar E, Ivan C, Aslan B, Mai J, He G, Mangala LS, Jiang D, Nagaraja AS, Ozpolat B, Chavez-Reyes A, Ferrari M, Mitra R, Siddik ZH, Shen H, Yang X, Sood AK, Lopez-Berestein GEBioMedicineCorrigendum to "PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis" [EBioMedicine 40 (2019) 290-304]. EBioMedicine. 2022 Sep; 83:104194.EBioMedicine2022-07-29T00:00:002022Corrigendum to "PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis" [EBioMedicine 40 (2019) 290-304].36077735Stur E, Bayraktar E, Dal Molin GZ, Wu SY, Mangala LS, Yao H, Wang Y, Ram PT, Corvigno S, Chen H, Liang H, Tworoger SS, Levine DA, Lutgendorf SK, Liu J, Moore KN, Baggerly KA, Karlan BY, Sood AKCancersMolecular Analysis of Short- versus Long-Term Survivors of High-Grade Serous Ovarian Carcinoma. Cancers (Basel). 2022 Aug 30; 14(17).Cancers (Basel)2022-08-30T00:00:002022Molecular Analysis of Short- versus Long-Term Survivors of High-Grade Serous Ovarian Carcinoma.Authorship 10645544Authorship 10644282036824283Glassman D, Kim MS, Spradlin M, Badal S, Taki M, Bhattacharya P, Dutta P, Kingsley CV, Foster KI, Animasahun O, Jeon JH, Achreja A, Jayaraman A, Kumar P, Nenwani M, Wuchu F, Bayraktar E, Wu Y, Stur E, Mangala L, Lee S, Yap TA, Westin SN, Eberlin LS, Nagrath D, Sood AKiScienceExploiting metabolic vulnerabilities after anti-VEGF antibody therapy in ovarian cancer. iScience. 2023 Feb 17; 26(2):106020.iScience2023-01-19T00:00:002023Exploiting metabolic vulnerabilities after anti-VEGF antibody therapy in ovarian cancer.36835335Dasari SK, Joseph R, Umamaheswaran S, Mangala LS, Bayraktar E, Rodriguez-Aguayo C, Wu Y, Nguyen N, Powell RT, Sobieski M, Liu Y, Chowdhury MA, Amero P, Stephan C, Lopez-Berestein G, Westin SN, Sood AKInternational journal of molecular sciencesCombination of EphA2- and Wee1-Targeted Therapies in Endometrial Cancer. Int J Mol Sci. 2023 Feb 15; 24(4).Int J Mol Sci2023-02-15T00:00:002023Combination of EphA2- and Wee1-Targeted Therapies in Endometrial Cancer.Authorship 10681414Authorship 10677191837031740Liu Y, Ahumada AL, Bayraktar E, Schwartz P, Chowdhury M, Shi S, Sebastian MM, Khant H, de Val N, Bayram NN, Zhang G, Vu TC, Jie Z, Jennings NB, Rodriguez-Aguayo C, Swain J, Stur E, Mangala LS, Wu Y, Nagaraju S, Ermias B, Li C, Lopez-Berestein G, Braam J, Sood AKJournal of controlled release : official journal of the Controlled Release SocietyEnhancing oral delivery of plant-derived vesicles for colitis. J Control Release. 2023 05; 357:472-483.J Control Release2023-04-20T00:00:002023Enhancing oral delivery of plant-derived vesicles for colitis.37100807LaFargue CJ, Amero P, Noh K, Mangala LS, Wen Y, Bayraktar E, Umamaheswaran S, Stur E, Dasari SK, Ivan C, Pradeep S, Yoo W, Lu C, Jennings NB, Vathipadiekal V, Hu W, Chelariu-Raicu A, Ku Z, Deng H, Xiong W, Choi HJ, Hu M, Kiyama T, Mao CA, Ali-Fehmi R, Birrer MJ, Liu J, Zhang N, Lopez-Berestein G, de Franciscis V, An Z, Sood AKNature communicationsOvercoming adaptive resistance to anti-VEGF therapy by targeting CD5L. Nat Commun. 2023 04 26; 14(1):2407.Nat Commun2023-04-26T00:00:002023Overcoming adaptive resistance to anti-VEGF therapy by targeting CD5L.Authorship 1087850438279277Joseph R, Dasari SK, Umamaheswaran S, Mangala LS, Bayraktar E, Rodriguez-Aguayo C, Wu Y, Nguyen N, Powell RT, Sobieski M, Liu Y, Kim MS, Corvigno S, Foster K, Hanjra P, Vu TC, Chowdhury MA, Amero P, Stephan C, Lopez-Berestein G, Westin SN, Sood AKInternational journal of molecular sciencesEphA2- and HDAC-Targeted Combination Therapy in Endometrial Cancer. Int J Mol Sci. 2024 Jan 20; 25(2).Int J Mol Sci2024-01-20T00:00:002024EphA2- and HDAC-Targeted Combination Therapy in Endometrial Cancer.true1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1InstructorInstructortrue1Assistant ProfessorAssistant Professortrue1InstructorInstructortrue1ProfessorProfessortrue1Assistant ProfessorAssistant Professor24799285Yang L, Moss T, Mangala LS, Marini J, Zhao H, Wahlig S, Armaiz-Pena G, Jiang D, Achreja A, Win J, Roopaimoole R, Rodriguez-Aguayo C, Mercado-Uribe I, Lopez-Berestein G, Liu J, Tsukamoto T, Sood AK, Ram PT, Nagrath DMolecular systems biologyMetabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer. Mol Syst Biol. 2014 May 05; 10:728.Mol Syst Biol2014-05-05T00:00:002014Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer.